Italia markets close in 1 hour 53 minutes
FTSE MIB
32.903,54 +238,33 (+0,73%) Dow Jones
38.484,56 -104,60 (-0,27%) Nasdaq
17.685,48 -3,41 (-0,02%) Nikkei 225
38.102,44 -712,12 (-1,83%) Petrolio
79,04 +0,59 (+0,75%) Bitcoin EUR
61.012,38 -1.105,60 (-1,78%)
NBIX Sep 2024 160.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 01:21PM EDT. Mercato aperto.
| Chiusura precedente | 5,10 |
| Aperto | 5,10 |
| Denaro | 0,00 |
| Domanda | 0,00 |
| Prezzo d'esercizio | 160,00 |
| Scadenza | 2024-09-20 |
| Min-Max giorno | 5,10 - 5,10 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1,21k |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.